Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02029560
Other study ID # JWP-SDS-405
Secondary ID
Status Completed
Phase N/A
First received November 25, 2013
Last updated March 6, 2018
Start date November 2013
Est. completion date November 2014

Study information

Verified date March 2018
Source JW Pharmaceutical
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

To evaluate effect on cardiovascular system(blood pressure) when Thrupas® capsule is administered every day for 12 weeks in patients with Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia


Description:

BPH and hypertension are chronic senile diseases that increase in prevalence with age. It is reported that 25% of men over 60 years old suffer from both BPH and hypertension. Though these two diseases differ in nature, there is a hypothesis advanced from recent studies that for both diseases, increase in sympathetic tone plays an important role in pathophysiology.

As a medical treatment of BPH, α-blockers are widely selected in clinical studies as a first line treatment in patients with LUTS, for its non-invasiveness and superior clinical efficacy [1, 5]. Such α-blockers increases urine flow and decreases residual urine by controlling excitement of the sympathetic nervous system distributed around smooth muscle of prostate and bladder neck. Through this, α-blockers improve conditions of clinical symptoms of patients suffering from LUTS due to BPH, and decrease need for invasive surgery related to BPH, and also have medical action to decrease morbidity rate of secondary complications of BPH such as acute retention of urine, deterioration of renal function, bladder stone and urinary tract infection.

However, in the case of patients who are on hypertension medication, when considering concomitant administration with α-blockers, adverse events such as orthostatic hypotension and dizziness due to drop in blood pressure is most concerned. In this regard, silodosin, as an alpha 1A adrenoceptor antagonist, has been proven have low occurrence of adverse events related to cardiovascular system and have little effect on blood pressure compared to other α-blockers.

Thus, in this study, we aim to see the effect on cardiovascular system(blood pressure) Thrupas® capsule is administered every day for 12 weeks in patients with LUTS suggestive of BPH.


Recruitment information / eligibility

Status Completed
Enrollment 400
Est. completion date November 2014
Est. primary completion date November 2014
Accepts healthy volunteers No
Gender Male
Age group 50 Years and older
Eligibility Inclusion Criteria:

Patients who have been diagnosed with BPH by digital rectal exam or ultrasonographic findings and meet the following criteria.

1. Male, 50 years or older

2. Patients with a total I-PSS score = 8

3. Patients with a QoL score = 3

4. Patients who voluntarily decided to participate and have filled out consent form

Exclusion Criteria:

1. Patients with an allergy to a-blockers

2. Patients with history of severe arrhythmia, cardiac failure, cardiac infarction, unstable angina, cerebral infarction within 6 months

3. Patients with severe hepatic disorders (hepatic insufficiency, cirrhosis, jaundice, hepatoma)

4. Patients with renal dysfunction

5. Has PSA value = 10ng/ml or has been diagnosed with tumor by biopsy even if PSA value is lower than 10ng/ml,

6. Patients with history of prostate surgery

7. Patients previously administered with 5a-reductase inhibitor within 3 months

8. Patients previously administered with a1-adrenoceptor antagonist within 1 month

9. Patients who are taking the following drugs at the start of study or those who have to take during the 12 weeks of the study: aß-adrenoceptor antagonist, a-adrenoceptor agonist, anticholinergic (tolterodine, oxybutynin, etc.)

10. Patients with a history of intrapelvic radiation therapy or prostatic hyperthermia

Study Design


Locations

Country Name City State
Korea, Republic of Hallym University Sacred Heart Hospital Anyang-si Gyeonggi-do
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Gangam Severance Hospital Seoul
Korea, Republic of Seoul St. Mary's Hospital of the Catholic University of Korea Seoul

Sponsors (1)

Lead Sponsor Collaborator
JW Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in blood pressure (systolic, diastolic) before and after administration 3 months
Secondary Change in IPSS total score before and after administration* 3 months
Secondary Change in QoL score before and after administration 3 months
Secondary Change in IPSS subscore before and after administration 3 months
Secondary Evaluation of BSW after administration 3 months
Secondary Change in Qmax before and after administration 3 months
Secondary Adverse events 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT04807296 - Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP) N/A
Recruiting NCT05574244 - Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction N/A
Recruiting NCT04288427 - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy N/A
Not yet recruiting NCT04245566 - Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH Phase 3
Completed NCT03246880 - Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients Phase 3
Completed NCT02509975 - Safety and Efficacy of OCL 503 in Prostate Artery Embolization N/A
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Completed NCT02283684 - GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT Phase 4
Completed NCT02206243 - Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
Completed NCT01454349 - Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) Phase 1/Phase 2
Completed NCT01438775 - Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) Phase 3
Completed NCT01139762 - A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Phase 3
Completed NCT01152190 - A Study in Benign Prostatic Hyperplasia Phase 3
Active, not recruiting NCT00400894 - Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma N/A
Unknown status NCT00381108 - Study of the Effects of Pomegranate Tablets on Enlarged Prostates Phase 1
Completed NCT00701779 - Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Phase 4
Completed NCT00224133 - The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months Phase 3
Terminated NCT02962674 - To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH. N/A
Active, not recruiting NCT05415748 - Deprescribing Tamsulosin in Older Men Phase 4
Recruiting NCT04853914 - Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound. N/A